U-Synbio Secures Tens of Millions RMB in Angel Funding to Advance Live Biotherapeutic Products Using Synthetic Biology

Recently, Suzhou U-Synbio Technology Co., Ltd. (hereinafter referred to as “U-Synbio”) completedTens-of-millions-level angel round financing, jointly invested by Inno Angel, Suzhou Industrial Park Science and Technology Innovation Fund, and Shuimu Tsinghua. The funds raised in this round will be primarily used for team development, laboratory construction, the development of a series of pipeline products, as well as the optimization and upgrading of core technology platforms and external collaborations.

Youxin Hesheng was established in 2021,Dr. Chen Jingyu, Founder of the CompanyA graduate of Tsinghua University, with work experience at the USDA Western Regional Research Center and the University of California, Davis, U-Synbio is a technology-driven synthetic biology company specializing in medical applications. In 2021, U-Synbio was honored as a Science and Technology Leading Talent Project in Suzhou Industrial Park. In the coming years, U-Synbio will leverage synthetic biology technologies to enhance its live biotherapeutic platform, focusing on the development of a pipeline of products for rare metabolic disorders, thereby creating greater value for human health.

Dr. Chen Jingyu expressed her heartfelt gratitude for the investors’ recognition and support: “The rapid advancement of synthetic biology has made it possible to apply biotechnology across multiple fields. The founding team of Uxin Hesheng has been deeply engaged in the field of synthetic biology for many years and is well-versed in the requirements of innovative drug development. With the goal of developing LBP-based innovative drugs, Uxin Hesheng has established an LBP synthetic biology engineering platform, providing novel solutions for the treatment of various diseases. Moving forward, Uxin Hesheng will build on this foundation to accelerate product pipeline development and clinical trial applications, continuing to demonstrate the immense potential of synthetic biology and delivering efficient, high-quality therapeutic solutions to meet the needs of precision and personalized medicine.”

Live Biotherapeutic Products (LBP) are living organisms designed and developed to treat, cure, or prevent human diseases. LBP represents a completely new pharmaceutical field that leverages synthetic biology tools, enabling chassis bacteria to be engineered to sense and respond to environmental signals, thereby consuming harmful compounds and delivering therapeutic agents.

Synthetic biology is a discipline that combines biological science with engineering to design and construct biological genomes and systems with novel biological functions. Synthetic biology has ushered in the third biotechnology revolution and stands as one of the disruptive technologies leading the 21st century. Live Biotherapeutic Products (LBPs) based on gene-edited organisms represent a significant medical application of synthetic biology and are among the key research hotspots in the global scientific community.

Zhu Xiaocheng, Partner at Inno AngelIt was stated that synthetic biology has been widely applied in the production of natural products and the development of new materials, yet remains largely unexplored in the field of clinical therapy. The development of LBP drugs in combination with probiotics offers a novel approach to treating metabolic diseases. InnoCare is optimistic about the application of synthetic biology technologies and has already invested in several cutting-edge technology companies. Dr. Chen Jingyu, founder of Uxin, and his R&D team possess substantial technical expertise in the LBP domain. Multiple pipeline candidates are expected to enter clinical trials within the next two to three years, addressing patients’ treatment needs and safeguarding public health.

Zhao Yuxu, Project Leader of the Park Science and Technology Innovation Fund, InvestorIt is stated that the project leverages synthetic biology technologies to develop Live Biotherapeutic Products (LBPs), offering an effective solution to the challenges posed by inherited metabolic disorders. As a platform-type company in the biotechnology sector, it holds significant potential for value appreciation. The core team has been dedicated to the research and development of synthetic biology and microbial strains for many years. Through a strong alliance with professionals possessing extensive clinical and entrepreneurial experience, the team is well-positioned to accelerate product commercialization. This investment in Youxin Hesheng further aims to strengthen and refine the biomedical industry ecosystem within Suzhou Industrial Park, thereby enhancing regional innovation capabilities.

Li Zhu, Partner at the Tsinghua Alumni FundStatement: Dr. Chen Jingyu earned his Ph.D. from Tsinghua University, where he studied under Professor Chen Guoqiang, a renowned expert in synthetic biology, and has developed a profound understanding of synthetic biology technologies. The live biotherapeutic products (LBPs) developed by his team have demonstrated significant promise in the treatment of various rare diseases and metabolic disorders. Shuimu Tsinghua Capital is optimistic that, under the leadership of alumnus Professor Chen, Youxin will accelerate the market launch of multiple LBP drug candidates, thereby enriching the arsenal of clinical therapeutic options.

Inno Angel Fund was established in April 2013, with RMB 5 billion under management, and has invested in over 500 innovative projects to date. The investment management team averages more than 10 years of angel investment experience. Building on its foundation of Tsinghua University alumni, the fund has developed a multi-dimensional startup support ecosystem. Committed to becoming a self-evolving, innovative angel investment platform, Inno Angel Fund adheres to the mission of “Investing in Innovation, Achieving Mutual Success.” It has deeply cultivated key entrepreneurial hubs including Beijing, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and Silicon Valley in the United States, establishing a cross-regional network for investment and startup services. The fund is characterized by high investment efficiency, a high success rate in subsequent financing rounds, and rapid return on investment.

Inno Angel Fund focuses on new energy, advanced manufacturing (semiconductors/robotics/aerospace, etc.), next-generation information technology, and life sciences. It primarily invests in the angel and Pre-A stages. 70% of Inno’s portfolio companies have secured subsequent funding rounds, with multiple projects initiating IPOs.

Meanwhile, Inno Angel Fund offers comprehensive post-investment services, significantly accelerating portfolio companies’ growth through support in fundraising, debt financing, public relations, human resources, finance and taxation, due diligence (DD), founder training, and connections with resources from large corporations. It has also established a complete, closed-loop entrepreneurship service ecosystem, with extensive coverage in innovation spaces, entrepreneurial media and communications, entrepreneurial learning and communities, and resource integration, earning widespread recognition from entrepreneurs and industry institutions.

Since its inception, Inno Angel Fund has repeatedly received industry recognition and honors, including Zero2IPO’s “Top 10 Early-Stage Investment Firms in China,” Huaxing Capital’s “Best Angel Investment Firm,” 36Kr’s “Top 3 Early-Stage Investment Firms Most Preferred by LPs in China,” and ChinaVenture’s “China’s Best Early-Stage Venture Capital Firm of the Year.”

Lingjun Venture Capital, established in December 2012 and wholly owned by the Suzhou Industrial Park Enterprise Development Service Center, is currently the largest policy-oriented angel investment institution in Suzhou Industrial Park. The investing entity for this initiative, the Park Science and Technology Innovation Fund, was jointly established with Lingjun Venture Capital serving as the General Partner (GP) and the Suzhou Industrial Park Finance and Audit Bureau acting as the Limited Partner (LP). With a total size of RMB 1.5 billion for its first phase, the fund focuses on key strategic emerging industries such as biopharmaceuticals, nanotechnology applications, and artificial intelligence, aiming to support technology-driven and innovative enterprises within the park in achieving greater scale, quality, and competitiveness.

Shuimu Tsinghua Alumni Fund was established in October 2014. Its founding partners include Li Zhu (Class of 1984, Computer Science), Du Yan (Class of 1981, Environmental Engineering), and Yu Longwen (Class of 1984, Materials Science), among others. As the first university alumni fund in China, its General Partners (GPs) and Limited Partners (LPs) are exclusively Tsinghua University alumni, and it invests solely in ventures founded by Tsinghua alumni. The fund’s core competency lies in deeply sourcing alumni-led startups at the seed or angel stage, leveraging the Tsinghua alumni network to provide comprehensive empowerment. It offers all-around support to alumni entrepreneurs in areas such as financing, sales, team building, and cognitive development. The vision of Shuimu Tsinghua Alumni Fund is to become the first stop for alumni entrepreneurship, issuing the first check to alumni founders. It also aims to connect with 10,000 alumni entrepreneurs and invest in 100 publicly listed companies over a 20-year period. Currently, Shuimu Tsinghua Alumni Fund is about to launch its third fund, with Wang Xuehui (Class of 1999, Automotive Engineering) serving as Executive Director. We warmly welcome alumni to recommend early-stage alumni ventures to the fund.